All In MedTech

FDA Clearance Tracker · P000043-S010

TMX-3000 THERMATRX OFFICE THERMOTHERAPY SYSTEM

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 8, 2007 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 8, 2007

Approved

Time to decision

387 days

Received Jan 17, 2006. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P000043-S010
Device name
TMX-3000 THERMATRX OFFICE THERMOTHERAPY SYSTEM
Applicant location
Marlboro, MA
Received
Jan 17, 2006
Decided
Feb 8, 2007
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P000043

Device type

Device class
Class III

Every decision under product code MEQ

FDA's approval statement

As written in FDA's record.

APPROVAL FOR AN UPGRADE OF THE DEVICE INCLUDING A MODIFICATION OF THE MAIN CONSOLE, COMPUTER AND SOFTWARE. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME TMX-3000 THERMATRX OFFICE THERMOTHERAPY SYSTEM AND IS INDICATED FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WHO HAVE A MINIMUM PROSTATIC URETHRA LENGTH F 25 MM AND A TOTAL PROSTATE VOLUME BETWEEN 30 AND 100 CC.

Source documents

Other decisions for Boston Scientific Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.